Taizhou, China

Yanling He

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Shanghai Aryl Pharmtech Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yanling He. Retrieved from https://idiyas.com/inventor/yanling-he-unn1p4uy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yanling He and Pharmaceutical Innovation

Introduction

Yanling He is an inventor associated with Taizhou, China, whose patent work concerns pharmaceutical compounds and their potential medical applications. The available information lists 1 patent in her name.

Latest Patents

Her listed patent, “Tetracyclic Derivative, Method for Preparing Same and Use Thereof in Medicine,” describes a tetracyclic derivative, methods for preparing it, and pharmaceutically acceptable salts. The invention identifies the compound as a potential therapeutic agent, particularly as a K-Ras GTPase inhibitor. The patent also defines the substituents in general formula (I) in its description.

Career Highlights

He is associated with Zhejiang Hisun Pharmaceutical Co., Ltd. and Shanghai Aryl Pharmtech Co., Ltd. Her listed patent reflects work at the intersection of medicinal chemistry and therapeutic research.

Collaborations

Her listed coworkers include Youxi Chen and Chaoying Cheng.

Conclusion

Yanling He’s patent record highlights research into tetracyclic derivatives and their potential use in medicine, including as K-Ras GTPase inhibitors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…